Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Congress abstract: ASCO 2025 Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • الموضوع:
      2025
    • Collection:
      Newcastle University: Figshare
    • نبذة مختصرة :
      presented at ASCO 2025 to communicate the results from the Phase 3 OASIS 4 trial which evaluated the safety and efficacy of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy.
    • Relation:
      https://figshare.com/articles/conference_contribution/Congress_abstract_ASCO_2025_Efficacy_and_safety_of_elinzanetant_for_vasomotor_symptoms_associated_with_adjuvant_endocrine_therapy_Phase_3_OASIS_4_trial/29583212
    • الرقم المعرف:
      10.71943/bayer.figshare.29583212.v1
    • الدخول الالكتروني :
      https://doi.org/10.71943/bayer.figshare.29583212.v1
      https://figshare.com/articles/conference_contribution/Congress_abstract_ASCO_2025_Efficacy_and_safety_of_elinzanetant_for_vasomotor_symptoms_associated_with_adjuvant_endocrine_therapy_Phase_3_OASIS_4_trial/29583212
    • Rights:
      CC BY-ND
    • الرقم المعرف:
      edsbas.BCB780E2